Table 2.

Baseline Characteristics Favoring Response in Dupilumab Studies

Baseline Characteristics	Rationale	Other Considerations
Blood eosinophil count > 300 cells/mm3	Greatest reduction in asthma exacerbations happened in this cohort	Elevations of eosinophil count above 3000 cells/mm3 in 1.2% of patients on dupilumab
Blood eosinophil count > 150 cells/mm3	Asthma exacerbations and FEV1 were not better than placebo with eosinophils < 150 cells/mm3
FENO > 25 ppb	Asthma exacerbations and FEV1 were not better than placebo with lower FENO

Abbreviations: FE_NO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in one second; ppb, parts per billion.